Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Buy rating and a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage